The Patent Finder
US

Peptide Pharmaceuticals

US 10,420,844 In force
OverviewFamilyAssignmentsSources & methods
Collateral for a security interest recorded May 14, 2025 (Hercules Capital, Inc.).

Term ends May 17, 2032 · High confidence

Filed Mar 6, 2018 as application 15/913,845 · Granted Sep 24, 2019
Base term, 20 years from filing
Today
20 years from filing
2012 2032
Clock starts
May 17, 2012
Term ends
May 17, 2032
Granted
Sep 24, 2019
base term fee events Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
1 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.

This patent's term is its 20-year base term, with no adjustment for prosecution delay. 1 of 3 maintenance fees is paid so far. Confidence: High. from the record

How we calculated this date

One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
StepInputDate after this stepConfidence
Base term, 20 years from filingClock starts May 17, 2012, when application PCT/US2012/038429, the earliest non-provisional in its chain, was filed (this one was filed Mar 6, 2018)May 17, 2032High confidence
Continuity chainEvery parent in the chain resolvedno changeHigh confidence
Patent term adjustmentNone on fileno changeHigh confidence
Terminal disclaimer capNone on recordno cap appliedHigh confidence
Patent term extensionNone on fileno changeHigh confidence
Fee events1 of 3 maintenance fees paidIn forceHigh confidence
Computed term endThe steps above, in orderMay 17, 2032High confidence

This family

Application PCT/US2012/038429PCT application
no patent term
no patent term
US 10,010,617In force
Oct 2032
Oct 2032
US 10,420,844this patent
May 2032
May 2032
Application 16/579,799Abandoned
not computed
not computed
Application 16/826,208Abandoned
not computed
not computed
Application 19/396,030Pending
not computed
not computed
Application 19/405,218Pending
not computed
not computed
Every application listed has its file history here. The family may have others.

Assignments

Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
RecordedAssignorAssigneeConveyance
Jun 1, 2018
Reel 45963, frame 694
Nestor, John J.Eumederis Pharmaceuticals, Inc.Assignment of Assignor's Interest
Jul 20, 2019
Reel 49809, frame 925
Eumederis Pharmaceuticals Inc.Mederis Diabetes Inc.Assignment of Assignor's Interest
Feb 19, 2025
Reel 70266, frame 875
Mederis Diabetes, LLCMederis Diabetes LLCAffidavit of Address Change
May 14, 2025
Reel 71108, frame 692
Altimmune, Inc.; Spitfire Pharma, LLCHercules Capital, Inc., as AgentSecurity Interest

Sources

Google Patents · The patent document at USPTO · Assignment records at USPTO

USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup

Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited